Madrigal Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapies for liver and metabolic diseases, including its treatment for nonalcoholic steatohepatitis (NASH/MASH).
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Steve Cohen / Point72 | 76 | Trimmed -39% | 142,629 | $76,584,642 | 0.1% |
| Paul Tudor Jones / Tudor | 63 | Trimmed -1% | 11,509 | $6,179,758 | 0.0% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-09-24.